Add time:09/04/2019         Source:sciencedirect.com

SummaryBackgroundTreatment options for recurrent glioblastoma are scarce, with second-line chemotherapy showing only modest activity against the tumour. Despite the absence of well controlled trials, bevacizumab is widely used in the treatment of recurrent glioblastoma. Nonetheless, whether the high response rates reported after treatment with this drug translate into an overall survival benefit remains unclear. We report the results of the first randomised controlled phase 2 trial of bevacizumab in recurrent glioblastoma.

We also recommend Trading Suppliers and Manufacturers of Lomustine (cas 13010-47-4). Pls Click Website Link as below: cas 13010-47-4 suppliers